Included in the review were items such as clarification of the primary intent of screening to detect and address clinically significant disorders versus carriers, clarification of use of the abbreviation A2 as the name of a peak in the commercial HPLC tracing rather than the name of a specific hemoglobin (Hb A2), and recognition of the possibility for faster follow-up using filter paper specimens rather than whole blood (particularly important during the time of restricted patient travel as a result of COVID-19). This evidence concerns the gene GSTM1 and COVID-19.